INS and type 1 diabetes mellitus: The Diabetes Control and Complications Trial (DCCT), which enrolled relatively young adults with type 1 diabetes (T1D), demonstrated a non-significant trend toward reduced CV events with improved glycemic control (average HbA1c in the intensively insulin-treated group was 7% and that in the usual care group was 9%).